Summary
For Year 2026-27, Alembic Pharmaceuticals reports the following shareholding: Total Promoters at 69.74%, Mutual Fund at 8.18%, Insurance at 7.68%, Foreign Institutional Investors at 4.26%, Domestic Institutional Investors at 0.31%, and Retail at 9.83%. This breakdown provides a quick snapshot of ownership distribution for Alembic Pharmaceuticals in 2026-27.
Alembic Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Alembic Pharmaceuticals stands at 69.74% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Alembic Pharmaceuticals is 4.26% and 0.31% respectively.
The retail shareholding of the Alembic Pharmaceuticals is 9.83%.
Changes in shareholding patterns of Alembic Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Alembic Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Alembic Pharmaceuticals Associated Pages
- Alembic Pharmaceuticals Share Price
- Alembic Pharmaceuticals Share Price chart
- Alembic Pharmaceuticals Fundamental Analysis
- Alembic Pharmaceuticals Technical Analysis
- Alembic Pharmaceuticals Peer Comparison
- Alembic Pharmaceuticals Share Price History
- Alembic Pharmaceuticals Dividend
- Alembic Pharmaceuticals Board of Directors
